Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

Clin Infect Dis. 1996 Jun;22(6):938-43. doi: 10.1093/clinids/22.6.938.

Abstract

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommended a total dose of AmBisome of > or = 20 mg/kg, given in > or = 5 doses of 3-4 mg/kg over > or = 10 days.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amphotericin B / administration & dosage*
  • Amphotericin B / adverse effects
  • Animals
  • Antifungal Agents / administration & dosage
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Drug Carriers
  • Female
  • Humans
  • Infant
  • Leishmania infantum / isolation & purification
  • Leishmaniasis, Visceral / drug therapy*
  • Liposomes
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Drug Carriers
  • Liposomes
  • Amphotericin B